Abbott Tricor adds tablets with HDL indication
This article was originally published in Pharmaceutical Approvals Monthly
Tricor (fenofibrate) is approved Sept. 5 in two tablet strengths, 54 mg and 160 mg. Abbott's lipid-lowering agent was launched in 1998 as a 67 mg micronized capsule for treatment of type II, IV, and V hyperlipidemia and is also available as 134 mg and 200 mg capsules. The tablet formulation received approval for an additional claim that the capsule does not have: increasing HDL cholesterol in patients with primary hypercholesterolemia or mixed dyslipidemia, according to the company
You may also be interested in...
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.
Broader than initially reported, Merck & Co.’s agreement with BARDA extends beyond J&J’s recently authorized vaccine to other COVID-19 vaccines and therapeutics as needed.
White House, Democrat majority in Congress and likely next FTC chair support the agency wielding the authority, says advertising law attorney Holly Melton. Supreme Court, though, likely will rule in pending cases that a strict reading of an FTC regulation doesn’t grant monetary penalty authority.